Poor
Not Aligned
Patient Risk:
Moderate
Summary
Many core label facts are contradicted or materially misstated, particularly the active ingredients/composition, mechanism description, pediatric dosing implication, and timing/side effect/risk characterizations. Several statements are unsupported or conflict with label-directed directions (e.g., clear fluid timing and fluid restriction, mechanism).
Category Scores
Accurate Statements
SUPREP is a bowel preparation medication used to cleanse the colon before a colonoscopy.
Section 1 INDICATIONS AND USAGE: “cleansing of the colon as a preparation for colonoscopy” (adult and pediatric patients 12 years of age and older).
SUPREP is administered orally in a two-dose regimen.
Section 2 DOSAGE AND ADMINISTRATION / 17 PATIENT COUNSELING: “Two doses of SUPREP… One bottle… equivalent to one dose.” Also Section 14 Clinical Studies describes split-dose regimen.
The goal of Suprep cleansing is to produce clear or yellow liquid stool.
Label excerpt provided does not explicitly state “clear or yellow liquid stool.” (See omissions/unsupported for materiality.)
Unsupported Statements
Suprep contains polyethylene glycol 3350 as an active ingredient.
Label Description provided lists sulfate salts (sodium sulfate, potassium sulfate, magnesium sulfate) and inactive ingredients; no polyethylene glycol 3350 is listed.
Suprep contains electrolytes as an active ingredient.
Partially supported as the active ingredients are sulfate salts (sodium sulfate, potassium sulfate, magnesium sulfate). However “electrolytes” as a category claim is not explicitly used as “active ingredient” in the provided label; additionally several other claims about specific electrolyte identity are contradicted (see contradictions).
Suprep contains ascorbic acid as an active ingredient.
Label Description provided does not list ascorbic acid among active or inactive ingredients.
Suprep is combined with sodium sulfate.
Label indicates SUPREP contains sulfate salts; however the phrasing “combined with sodium sulfate” does not align clearly with the label’s composition statement (SUPREP kit contains sodium sulfate/potassium sulfate/magnesium sulfate).
Polyethylene glycol 3350 is an osmotic agent.
Polyethylene glycol 3350 is not identified in the provided label text as an ingredient; thus this mechanism statement is unsupported.
Polyethylene glycol 3350 draws water into the colon, which softens the stool and leads to a bowel movement.
Mechanism in label (Section 12.1) attributes osmotic water retention to unabsorbed sulfate anions/cations, not PEG, and does not mention PEG “softens the stool.”
The Suprep electrolytes include sodium sulfate, sodium chloride, and potassium chloride.
Label Description lists sodium sulfate, potassium sulfate, and magnesium sulfate (no sodium chloride or potassium chloride listed).
Suprep electrolytes help maintain electrolyte balance in the body.
Label warnings discuss disturbances caused by fluid/electrolyte abnormalities and advise hydration/correction, but do not state this positive “help maintain balance” claim.
Suprep electrolytes help prevent dehydration and imbalances that can occur with significant fluid loss.
Label advises adequate hydration and correction of abnormalities before treatment; it does not state electrolytes in SUPREP prevent dehydration/imbalances.
Ascorbic acid contributes to the solution's overall efficacy.
Ascorbic acid is not listed in provided label as an ingredient; thus efficacy attribution is unsupported.
Suprep is favored for palatability compared with older, larger-volume laxatives.
No palatability comparison or preference statement is present in the provided label excerpts.
Suprep uses an osmotic mechanism.
Supported that SUPREP is an osmotic laxative (Section 11 DESCRIPTION and Section 12.1 Mechanism of Action), but the subsequent mechanistic explanation references PEG (unsupported). This specific “osmotic mechanism” alone is supported; excluded from contradictions/unsupported where possible.
Other bowel preparation options include magnesium citrate.
Not addressed in provided label excerpts.
Other bowel preparation options include bisacodyl.
Not addressed in provided label excerpts.
Other bowel preparation options include various polyethylene glycol-based solutions.
Label mentions a marketed polyethylene glycol plus electrolytes bowel preparation as a comparator in a study, but does not list it as an “other option.”
The first dose of Suprep is typically consumed the evening before the colonoscopy.
Supported for pediatric study regimen using 4.5-ounce doses (evening before). For adults, the provided label excerpt states “split-dose regimen” but does not specify “evening before” timing in the adult section.
The second dose of Suprep is taken the morning of the procedure.
Supported for pediatric “split-dose” regimen (morning of exam) in provided label excerpt; adult timing not explicitly specified in excerpt.
The Suprep powder is mixed with a specified amount of water.
Provided label excerpt says “Must dilute SUPREP Bowel Prep Kit in water before ingestion,” but does not include the “powder” wording or specify mixing instructions in the supplied text.
Additional clear fluids are consumed within a set timeframe after each dose of Suprep to ensure adequate hydration.
Label excerpt provides “Must consume additional water after each dose” but does not provide “within a set timeframe after each dose.”
Common side effects of Suprep include vomiting.
No adverse reaction frequency/listing is provided in the excerpts. (Label counseling includes contacting for significant vomiting, but that is not the same as “common side effects.”)
Common side effects of Suprep include abdominal fullness.
Not present in the provided excerpts.
Common side effects of Suprep include bloating.
Not present in the provided excerpts.
The effects of Suprep typically begin within one to two hours after taking the first dose.
No such onset/timing statement appears in the provided excerpts.
After the first dose, Suprep leads to bowel movements.
Not explicitly stated in the provided excerpts.
Suprep produces results over several hours.
Not explicitly stated in the provided excerpts.
Patients are typically advised to follow a clear liquid diet for a specified period before and during the preparation process when using Suprep.
Partially supported (light breakfast/clear liquids day before; clear liquids day of up to two hours prior; stop fluids at least 2 hours prior), but “during the preparation process” is broader than the provided explicit day-by-day instructions.
Contradictions
Low
AI Statement
Suprep contains polyethylene glycol 3350 as an active ingredient.
Label Reference
Section 11 DESCRIPTION lists active ingredients as sulfate salts (sodium sulfate, potassium sulfate, magnesium sulfate) and provides inactive ingredients; no PEG 3350 appears in the provided label text.
Low
AI Statement
The electrolytes in Suprep include sodium sulfate, sodium chloride, and potassium chloride.
Label Reference
Section 11 DESCRIPTION: adults bottle contains sodium sulfate, potassium sulfate, magnesium sulfate; no sodium chloride or potassium chloride listed.
Low
AI Statement
Suprep is combined with sodium sulfate.
Label Reference
Section 11 DESCRIPTION: SUPREP contains sodium sulfate/potassium sulfate/magnesium sulfate; the kit itself is not described as being “combined with” sodium sulfate in the provided excerpt.
Low
AI Statement
Suprep contains ascorbic acid as an active ingredient.
Label Reference
Section 11 DESCRIPTION: ascorbic acid is not listed as active or inactive ingredient in the provided excerpt.
Low
AI Statement
The goal of Suprep cleansing is to produce clear or yellow liquid stool.
Label Reference
Not supported by the provided label text excerpts (no explicit “clear or yellow liquid stool” goal statement).
Low
AI Statement
More serious, though less common, risks associated with Suprep can include dehydration.
Label Reference
Provided label excerpt (5.1) discusses dehydration signs after taking SUPREP and need to hydrate; however the label text does not support the characterization as “more serious, though less common risks.”
Important Omissions
Pediatric dosing nuance: for pediatric patients 12 years to 16 years, the 6-ounce per dose regimen is “not recommended,” and the evaluated effective regimen is two 4.5-ounce doses in split-dose manner.
Importance:
Moderate
Label-specific hydration and safety instructions: correct fluid/electrolyte abnormalities before treatment; advise adequate hydration before/during/after; consider post-colonoscopy labs (electrolytes, creatinine, BUN) after significant vomiting/dehydration or in renal-risk patients.
Importance:
Moderate
Key administration restrictions included in label excerpt: no solid food/milk; avoid red/purple-colored liquids; do not drink alcohol; do not take other laxatives; avoid oral medications within 1 hour of starting each dose; stop fluids at least 2 hours prior to colonoscopy.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Misstated ingredients (PEG 3350, ascorbic acid; incorrect electrolyte salts) and inaccurate/supporting mechanistic and timing claims could lead to misunderstanding of composition, mechanism, and administration/safety behaviors. Omission of pediatric regimen recommendation details and label-specific medication/fluid restrictions adds potential risk of incorrect use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple material inaccuracies vs label: active ingredient composition (PEG 3350, ascorbic acid; wrong electrolyte salts), and insufficient/uncertain support for dosing timing and adverse effect frequency/timing statements.
Suggested Improvement
Revise composition claims to match label active ingredients (sodium sulfate, potassium sulfate, magnesium sulfate) and remove PEG/ascorbic acid assertions; align mechanism description to sulfate osmotic effect (unabsorbed sulfate anions/cations retain water in GI tract); ensure split-dose timing claims are tied to label-supported wording; restrict adverse reaction statements to those explicitly supported in the provided label excerpts and characterize vomiting/dehydration as “signs” prompting contact rather than “common side effects” unless label frequency is provided; add pediatric regimen recommendation nuance (6-ounce doses not recommended) and include label-specific administration restrictions and lab/hydration warnings.